These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16303829)

  • 21. [Diabetics' life is about one third shorter. So you improve the prognosis of these high-risk patients].
    Stiefelhagen P
    MMW Fortschr Med; 2003 Apr; 145(15):18, 20. PubMed ID: 15104261
    [No Abstract]   [Full Text] [Related]  

  • 22. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.
    Betteridge DJ
    Fundam Clin Pharmacol; 2009 Dec; 23(6):675-9. PubMed ID: 19744248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Glitazone - mailing no 1. In response to DMW 49/2007].
    Traut V
    Dtsch Med Wochenschr; 2008 Feb; 133(6):261; author reply 262-3. PubMed ID: 18236356
    [No Abstract]   [Full Text] [Related]  

  • 24. In brief: rosiglitazone (Avandia) unbound.
    Med Lett Drugs Ther; 2014 Feb; 56(1435):12. PubMed ID: 24662977
    [No Abstract]   [Full Text] [Related]  

  • 25. [The effect of glitazones on the progression of type 2 diabetes and on cardiovascular endpoints].
    Schatz H
    Dtsch Med Wochenschr; 2005 Aug; 130(31-32):1825-30. PubMed ID: 16052448
    [No Abstract]   [Full Text] [Related]  

  • 26. Controversy over the cardiovascular effects of thiazolidinediones.
    Kapoor JR
    Am J Med; 2008 Apr; 121(4):e9. PubMed ID: 18374677
    [No Abstract]   [Full Text] [Related]  

  • 27. [Challenge in diabetes therapy: effects of glitazones beyond blood glucose control].
    Schernthaner G; Forst T; Gulba D; Haberbosch W; Hanefeld M; Linss G; März W; Mehnert H; Rosak C; Schnell O; Seufert J; Tschöpe D; Erdmann E
    Dtsch Med Wochenschr; 2009 Apr; 134(18):949-54. PubMed ID: 19384816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Future directions for insulin sensitizers in disease prevention.
    Colca JR
    Curr Opin Investig Drugs; 2007 Sep; 8(9):707-10. PubMed ID: 17729181
    [No Abstract]   [Full Text] [Related]  

  • 29. [Type 2 diabetic as cardiovascular risk patient].
    Krankenpfl J; 2005; 43(4-6):106. PubMed ID: 16171052
    [No Abstract]   [Full Text] [Related]  

  • 30. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
    Veneman TF
    Ned Tijdschr Geneeskd; 2006 Apr; 150(16):931-2; author reply 932-3. PubMed ID: 16686096
    [No Abstract]   [Full Text] [Related]  

  • 31. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
    Heine RJ
    Ned Tijdschr Geneeskd; 2006 Apr; 150(16):930-1; author reply 932-3. PubMed ID: 16686095
    [No Abstract]   [Full Text] [Related]  

  • 32. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
    Hiatt WR; Kaul S; Smith RJ
    N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
    [No Abstract]   [Full Text] [Related]  

  • 34. PROactive Study: (r)evolution in the therapy of diabetes?
    Ceriello A
    Diabet Med; 2005 Nov; 22(11):1463-4. PubMed ID: 16241907
    [No Abstract]   [Full Text] [Related]  

  • 35. Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?
    Vaccaro O; Riccardi G
    Nutr Metab Cardiovasc Dis; 2008 Feb; 18(2):85-7. PubMed ID: 18280715
    [No Abstract]   [Full Text] [Related]  

  • 36. Thiazolidinediones, deadly sins, surrogates, and elephants.
    Cleland JG; Atkin SL
    Lancet; 2007 Sep; 370(9593):1103-4. PubMed ID: 17905146
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R; Kupfer S; Erdmann E;
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diabetes drug safety update: Avandia and your heart.
    Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
    [No Abstract]   [Full Text] [Related]  

  • 39. [The true place of glitazones in the treatment of diabetes: after the PROactive study].
    Lindberg M; Jørgensen PH; Kampmann JP
    Ugeskr Laeger; 2006 Jun; 168(25):2477-9; author reply 2479-80. PubMed ID: 16824389
    [No Abstract]   [Full Text] [Related]  

  • 40. [Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].
    MMW Fortschr Med; 2003 Sep; 145(38):61. PubMed ID: 14603688
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.